Bard Medical Device Company Intelligence Report

Date: August 22, 2011
Pages: 48
Price:
US$ 515.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BAAE85C9333EN
Leaflet:

Download PDF Leaflet

Bard Medical Device Company Intelligence Report
Headquartered in Murray Hill, New Jersey, US, C.R. Bard (Bard) develops and manufactures medical, surgical, diagnostic and patient care devices. The company sells its products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the US and in more than 100 other countries, principally in Europe and Japan. In general, Bard’s products are intended to be used once and then discarded or implanted either temporarily or permanently.

Bard serves the healthcare industry through five divisions – Bard Access Systems Inc, Bard Electrophysiology Division, Bard Medical Division, Bard Peripheral Vascular Inc (including Bard Biopsy Systems) and Davol Inc – and four major product group categories – vascular, urology, oncology and surgical specialties. The company also has a product group of ‘Other Products’.

Vascular – Bard’s vascular products are produced by Bard Electrophysiology and Bard Peripheral Vascular. The company’s vascular products cover a wide range of minimally-invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, introducers and accessories; peripheral vascular stents and stent grafts, vena cava filters and biopsy devices; electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters; and fabrics, meshes and implantable vascular grafts.

Bard led the industry with the first angioplasty balloon catheter in 1980, giving cardiologists a safer and less costly alternative to open-heart procedures.

The January 2008 acquisition of the LifeStent range of stents from Edwards Lifesciences provided Bard with one of the broadest product offerings for peripheral vascular stenting.

The acquisition of Y-Med in November 2009 provided Bard with access to the VascuTrak catheter range.

More recently, the acquisition of FlowCardia in April 2010 expanded Bard’s portfolio of CTO endovascular products.

Urology – Bard claims to be the worldwide market leader in urological diagnostic and interventional products with a focus on urological drainage, continence and prostate disease management. Through its Bard Medical Division, the company has expanded its urology business to products in the areas of infection control, continence management, prostate management and catheter stabilisation.

The Foley catheter, which Bard introduced in 1934, remains one of the most important products in the urological field. Other urology products include: surgical slings used to treat stress urinary incontinence; faecal incontinence products; natural and synthetic devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; and specialty devices for ureteroscopic procedures and stone removal.

Bard entered the brachytherapy business in March 1998 with the purchase of Proseed Inc, which offered a turnkey programme that allows a hospital to implement brachytherapy treatment with lower investment cost and financial risk.

The acquisition of Venetec International in 2006 gave Bard access to the StatLock range of catheter stabilisation devices, which are used primarily to secure peripheral intravenous catheters.

Oncology – Bard’s oncology products and services are provided through Bard Access Systems, Bard Biopsy Systems and Bard Medical Division. They are designed for the treatment and management of various cancers and other diseases and disorders. These include specialty access catheters and ports; vascular access ultrasound devices, dialysis access catheters and enteral feeding devices.

The acquisition of Dymax Corp extended Bard Access Systems’ portfolio to include ultrasound systems that allow physicians to have real-time visualisation of needle placement.

The purchase of SenoRx in July 2010 enabled Bard to expand its breast biopsy business into the stereotactic X-ray segments.

Surgical Specialties – Bard maintains a complete line of advanced surgical specialty products and services to complement its focus on disease state management. These products are produced by Bard Medical and Davol and include implanted patches and fixation systems for hernia and other soft tissue repairs, irrigation devices for orthopaedic, laparoscopic and gynaecological procedures and products for topical haemostasis.

Other Products – The other product group includes irrigation, wound drainage and certain original equipment manufacturer (OEM) products.

Bard employs approximately 11,700 people. In 2010, the company generated net earnings of US$510 million on revenues of US$2.72 billion. Net sales in the first six months of 2011 reached US$1.43 billion.

Bard's shares are traded on the New York Stock Exchange. In August 2011, ValueAct Capital Management, a San Francisco, California-based hedge fund, announced that it held 6.5% of the company's shares.

This company report provides

Overview

Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review

Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus

Investigates the company’s aims and its areas of focus

Products

Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution

Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements

With whom has the company reached agreements and what do they involve?
Key contracts awarded

Mergers, Acquisitions, Minority Investments and Divestments

Litigation

Key Corporate Events


The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.
OVERVIEW

FINANCIAL REVIEW

First Half 2011 Financial Results
  Vascular
  Urology
  Oncology
  Surgical Specialty
  Other
2010 Financial results
  Vascular
  Urology
  Oncology
  Surgical Specialty
  Other
Five-Year Financial Data
Outlook
Employees

STRATEGIC FOCUS

PRODUCTS

Vascular
Urology
Oncology
Surgical Specialty

RESEARCH AND DEVELOPMENT

Product Pipeline
Studies and Trials
  RESILIENT Trial
  Bard Flair Endovascular Stent Graft

MANUFACTURING AND DISTRIBUTION

AGREEMENTS

Acacia Research’s Catheter Flushing Division
Covalon Technologies
RTI Biologics
Thermal Scalpel
Philips
Medegen
Genzyme
TyRx Pharma
Enpath Medical
CardioTech International (now AdvanSource Biomaterials)
Mentor
Tissue Science Laboratories
Mediwatch
Floreane Medical Implants
Specialized Health Products International
Endologix
Collagen (Allergan)
IS Pharma (formerly Maelor)
Integra LifeSciences

MERGERS AND ACQUISITIONS

Romedex International
SenoRx
Bard Sendirian
FlowCardia
PacerView Technologies Assets
Spire Corporation Assets
Y-Med
Brennen Medical
Specialized Health Products International
LifeStent Product Line from Edwards Lifesciences
Inrad
Venetec International
PST’s Self-Expanding Stent Assets
Genyx Medical
Sorenson Medical’s Closed Suction Catheter System
Onux Medical
Bridger Biomedical
Prostate Services of America, Amertek Medical and Alton Design
Biomedical Instruments and Products GmbH’s Biopsy Device
Source Tech Medical
Imagyn Medical Technologies - Rights to Seed Business
NMT Medical’s Vena Cava Filter Business
Mill-Rose Laboratories
Surgical Sense
Biosearch Medical Products’ Intermittent Urinary Catheter Business �38
Navarre Biomedical
Dymax
ProSeed
Endomatrix
Impra
American Hydro-Surgical Instruments
Vas Cath
Angiomed
Cardial
Bainbridge Sciences

JOINT VENTURES

Medicon

MINORITY INVESTMENTS

Hydromer

DIVESTITURES

Endoscopic Technologies Business
Cardiopulmonary Business
Intra-Aortic Balloon Catheter and Pump Business
Coronary Cath Lab Business
Neonatal Product Line
Surgical Suction Product Line
Sani-Spec Product Line
Sure-Closure System
Inspiron Division
MedSystems Division
Shield Healthcare Centers
Electromedical Systems

LITIGATION

Product Liability Matters
  Hernia Repair Implant Products
  Women’s Health Products
  Vena Cava Filter Products
Hologic
Atrium Medical and Endologix
Covidien
W.L. Gore & Associates
St Francis Medical Center
US Department of Health and Human Services, OIG

KEY CORPORATE EVENTS

LIST OF TABLES

SUMMARY OPERATING RESULTS
Recent Key Events
Bard - First Half 2011 Financial Results
Bard - First Half 2011 Sales by Product Area
Bard - First Half 2011 Sales by Geographic Area
Bard - Annual Financial Results, 2006-2010
Bard - Annual Sales by Geographic Area, 2006-2010
Bard - Annual Sales by Product Area, 2006-2010
Bard – Five-Year Financial Summary
Bard – Product Contributions to Net Sales, 2006-2010
Key Vascular Products
Key Urology Products
Key Oncology Products
Key Surgical Specialty Products
Bard - Annual R&D Expenditure, 2006-2010
Bard – Principal Offices and Manufacturing Locations
Agreements Summary
Mergers and Acquisitions Summary

LIST OF CHARTS

Bard - Annual Sales and Operating Income, 2006-2010
Bard - Annual Sales by Geographic Area, 2006-2010
Bard - Annual Sales by Product Area, 2006-2010
Bard - 2010 Sales by Product Group
Bard - Annual Vascular Product Sales, 2006-2010
Bard - Annual Urology Product Sales, 2006-2010
Bard - Annual Oncology Product Sales, 2006-2010
Bard - Annual Surgical Specialty Product Sales, 2006-2010
Skip to top


Ask Your Question

Bard Medical Device Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: